arguments are presented showing that 6-mp ( vii ) is expected 1 ) to function as a prophylactic agent against prostate cancer , 2 ) to represent an attractive therapeutic modality for palliative treatment of the hormone-responsive disease , and 3 ) to be compatible with other therapeutic modalities when very low prostatic levels of dht should be within reach .
C0376358
prostate cancer
C0033572
prostatic